Arrowstreet Capital, Limited Partnership Jounce Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$6.73 - $13.87 $92,389 - $190,407	-13,728 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$6.37 - $10.33 $173,588 - $281,502	-27,251 Reduced 66.5%	13,728 $96,000
Q3 2020 Nov 12, 2020	BUY	$4.58 - $10.95 $187,683 - $448,720	40,979 New	40,979 $334,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $78,069 - $233,403	-26,828 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$2.81 - $9.21 $75,386 - $247,085	26,828 New	26,828 $234,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.